Search
Search Results
##search.searchResults.foundPlural##
-
-
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1894PDF: 1441HTML: 673 -
MAGNUSIOMYCES CAPITATUS BREAKTHROUGH INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RECEIVING ECHINOCANDIN PROPHYLAXIS: CLINICAL FEATURES, MANAGEMENT, AND REVIEW OF THE LITERATURE
177PDF: 239Suppl. Files: 45Html: 121Html Suppl. Files: 109 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2676PDF: 895HTML: 496 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3955PDF: 1742HTML: 114 -
-
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1321PDF: 656HTML: 6942 -
DISTRIBUTION OF DIFFERENT PML/RAR? BCR ISOFORMS IN INDIAN ACUTE PROMYELOCYTIC LEUKAEMIA (APL) PATIENTS AND CLINICOHEMATOLOGICAL CORRELATION
1711PDF: 992HTML: 2264Response to reviewers comments: 236 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4169PDF: 1232HTML: 480 -
LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.
3967PDF: 1193HTML: 2520Figure 1: 248 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2762PDF: 1696HTML: 742 -
Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
1086PDF: 613HTML: 2237Cover Letter: 247 -
-
FIRST-PHASE INSULIN RESPONSE (FPIR) TO INTRAVENOUS GLUCOSE TOLERANCE TEST (IVGTT), INSULIN SENSITIVITY AND LONG-TERM FOLLOW-UP IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT) NORMOGLYCEMIC PATIENTS WITH REDUCED INSULIN SECRETION TO ORAL GLUCOSE TOLERANCE TEST: A PILOT STUDY. The function of the endocrine pancreas in transfusion-dependent ?-thalassemia
7669PDF: 670HTML: 375 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1719PDF: 987HTML: 407 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2644HTML: 362PDF: 986 -
PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome
1369PDF: 865HTML: 427 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3648PDF: 1493HTML: 2747 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3334PDF: 1709HTML: 408 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1623PDF: 879HTML: 381 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4249PDF: 1248HTML: 2129Fig.1: 249Fig. 2: 147Table 1: 255Table2: 275Table 3: 263 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2962PDF: 1264HTML: 3331 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3373PDF: 1441HTML: 4168 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3908PDF: 1367HTML: 3973Untitled: 289Untitled: 320 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4474PDF: 1625HTML: 486 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
4017PDF: 1783HTML: 11969Figures Haase: 304 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1786PDF: 1160HTML: 511 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1121PDF: 579HTML: 754 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
2812PDF: 1275HTML: 293







